8 Results for "

MOLM-13 human acute leukemia cells

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "MOLM-13 human acute leukemia cells" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-114228
CAS No.: 2093388-33-9
Purity:  98.21%
Research Areas:  

Cancer

PROTAC BET degrader-2 is a BET PROTAC degrader. PROTAC BET degrader-2 induces dose-dependent degradation of BRD2, BRD3 and BRD4 proteins in leukemia cells. PROTAC BET degrader-2 inhibits the growth of acute leukemia cells. PROTAC BET degrader-2 can be used for the research of acute leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-157334
CAS No.: 3032265-06-5
Purity:  99.03%
DEG-77 is a molecular glue targeting IKZF2 and CK1α, with DC50 values of 15.3 nM and 10 nM, respectively. DEG-77 exhibits significant anti-tumor activity, inducing increased transcriptional levels of the pro-apoptotic protein Bax and the cell cycle arrest protein p21. DEG-77 is applicable to the research of acute myeloid leukemia (AmL), diffuse large B-cell lymphoma and ovarian cancer.
loading...
    loading...
Cat. No.: HY-115881
CAS No.: 2769141-82-2
Purity:  98.60%
Research Areas:  

Cancer

SR-1114 is a ENL PROTAC degrader, with DC50 values of 150 nM, 311 nM and 1.65 μM in MV4;11, MOLM-13 and OCI/AML-2 cells, respectively. SR-1114 has an IC50 of 155 nM against the human CRL4CRBN complex. SR-1114 can be used in research related to acute leukemia and acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-122822
CAS No.: 2260944-68-9
GSK699 is a KAT2A/B/PCAF/GCN5 PROTAC degrader . GSK699 induces proteasome-dependent degradation of KAT2A, KAT2B, PCAF and GCN5, regulates the histone acetyltransferase activity of the SAGA complex, and reduces the level of histone H3K9ac. GSK699 inhibits the growth of neuroblastoma, acute myeloid leukemia and small cell lung cancer cells. GSK699 reduces the production of inflammatory cytokines and chemokines, and impairs LPS-stimulated immune cell responses. GSK699 is applicable to research related to acute myeloid leukemia, small cell lung cancer, neuroblastoma and inflammatory diseases .
loading...
    loading...
Cat. No.: HY-168741
Target:  

FLT3

Research Areas:  

Cancer

FLT3-ITD-IN-2 (Compound A1) is an inhibitor for FLT3-ITD kinase with an IC50 of 2.12 nM. FLT3-ITD-IN-2 inhibits the proliferation of FLT3-dependent human AML cell line MOLM-13 with an IC50 of 25.65 nM. FLT3-ITD-IN-2 exhibits antitumor efficacy against acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-149870
CAS No.: 2994191-89-6
Target:  

PROTACs CDK

Research Areas:  

Cancer

PROTAC CDK9 degrader-8 is a CDK9 PROTAC degrader that recruits cereblon. PROTAC CDK9 degrader-8 inhibits the growth of acute myeloid leukemia cells by inducing the degradation of CDK9 protein. PROTAC CDK9 degrader-8 can be used in studies related to CDK9-targeted degradation and acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-181690
Research Areas:  

Cancer

Menin-MLL-IN-37 is an orally active Menin-MLL protein complex inhibitor with an IC50 of 820.50 nM. Menin-MLL-IN-37 disrupts the interaction between menin and MLL proteins. Menin-MLL-IN-37 induces differentiation of acute myeloid leukemia cells and selectively inhibits the proliferation of MLL-rearranged and DNMT3A/NPM1-mutant leukemia cells. Menin-MLL-IN-37 can be used for the research of acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-181945
Research Areas:  

Cancer

FLT3-IN-39 (Compound W4) is a selective FLT3 inhibitor, with an IC50 value of 16.0 nM against FLT3-ITD and an IC50 value of 20.4 nM against FLT3-D835Y. FLT3-IN-39 inhibits FLT3-ITD and FLT3-D835Y mutant kinases. FLT3-IN-39 induces G0/G1 cell cycle arrest and Apoptosis in cancer cells, and reduces intracellular ROS levels. FLT3-IN-39 exhibits anti-tumor activity against acute myeloid leukemia .
loading...
    loading...